MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
Top Cited Papers
- 1 January 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (1), 205-215
- https://doi.org/10.1158/0008-5472.can-17-1636
Abstract
The immune checkpoint ligand PD-L1 and the transmembrane mucin MUC1 are upregulated in triple-negative breast cancer (TNBC), where they contribute to its aggressive pathogenesis. Here, we report that genetic or pharmacological targeting of the oncogenic MUC1 subunit MUC1-C is sufficient to suppress PD-L1 expression in TNBC cells. Mechanistic investigations showed that MUC1-C acted to elevate PD-L1 transcription by recruitment of MYC and NF-κB p65 to the PD-L1 promoter. In an immunocompetent model of TNBC in which Eo771/MUC1-C cells were engrafted into MUC1 transgenic mice, we showed that targeting MUC1-C associated with PD-L1 suppression, increases in tumor-infiltrating CD8+ T cells and tumor cell killing. MUC1 expression in TNBCs also correlated inversely with CD8, CD69, and GZMB, and downregulation of these markers associated with decreased survival. Taken together, our findings show how MUC1 contributes to immune escape in TNBC, and they offer a rationale to target MUC1-C as a novel immunotherapeutic approach for TNBC treatment. Significance: These findings show how upregulation of the transmembrane mucin MUC1 contributes to immune escape in an aggressive form of breast cancer, with potential implications for a novel immunotherapeutic approach. Cancer Res; 78(1); 205–15. ©2017 AACR.Keywords
Other Versions
Funding Information
- National Cancer Institute of the National Institutes of Health (R01 CA097098, R01 CA166480, R21 CA216553)
This publication has 49 references indexed in Scilit:
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approachesOncogene, 2012
- MUC1-C Oncoprotein Induces TCF7L2 Transcription Factor Activation and Promotes Cyclin D1 Expression in Human Breast Cancer Cells*Published by Elsevier BV ,2012
- Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cellsInternational Journal of Oncology, 2011
- A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast CancerJama-Journal Of The American Medical Association, 2011
- MUC1-C Oncoprotein Functions as a Direct Activator of the Nuclear Factor-κB p65 Transcription FactorCancer Research, 2009
- Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene DiscoveryPLOS ONE, 2009
- MUC1 Oncoprotein Blocks Death Receptor–Mediated Apoptosis by Inhibiting Recruitment of Caspase-8Cancer Research, 2008
- MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signallingNature, 2007
- Nuclear Import of the MUC1-C Oncoprotein Is Mediated by Nucleoporin Nup62Published by Elsevier BV ,2007
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006